FDA 483 - Remel Cleveland, a Division of Remel Inc. - November 20, 2019
An FDA inspection of Rem I, Inc. in Oakwood Village, OH, a medical device specification developer, revealed significant deficiencies in their quality system. The firm failed to adequately establish procedures for corrective and preventive actions, including trending, investigation thresholds, and verification of effectiveness. Additionally, complaint handling procedures were found to be inadequate, with issues such as missing complaints, unassigned cause codes, and insufficient investigation justifications.
ID · 09f49796-3b36-4809-97a3-9bdb2ca59bd5
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.